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Abstract
The process of angiogenesis refers to the growth of new blood vessels from 
existing ones. Tumours can produce factors in the micro-environment which act on 
blood vessels to promote angiogenesis. It is therefore considered to be fundamental 
in tumour progression and metastatic dissemination. This neovascularization can 
be regulated by numerous endogenous factors in the tumour micro-environment. 
As a result, anti-angiogenic therapies have been developed in the hope of targeting 
this process to reduce tumour growth and progression. However, only a proportion 
of patients respond to therapy, indicating the presence of treatment resistance in 
some. In this chapter, we aim to highlight the process of angiogenesis and to review 
pivotal evidence for the use of anti-angiogenic therapies thus far (alone and in 
combination with other agents). Finally, we will illustrate recent evidence for the 
discovery of biomarkers for anti-angiogenic therapies and potential mechanisms of 
resistance to such agents.
Keywords: angiogenesis, tumour microenvironment, blood vessels, growth factor, 
stroma, anticancer therapies, biomarkers, resistance mechanisms
1. Introduction
Angiogenesis is a process that is important to the growth of cancers. It refers 
to when new blood vessels sprout from existing ones. This multi-step process is 
imperative to the physiological maintenance of the body such as tissue repair [1]. 
It is also thought to be a critical process that tumours depend on for the delivery 
of oxygen and nutrients, in order to facilitate growth and progression [2]. Both 
pro-angiogenic factors and anti-angiogenic factors play a role in modulating 
tumour neovascularisation. Notably, vascular endothelial growth factors (VEGF) 
and catecholaminergic signalling pathways have been shown to be key factors in 
angiogenesis, invasion and metastases [3]. Investigations into catecholaminergic 
signalling from the sympathetic nervous system have shown to increase VEGF 
and matrix metalloprotease (MMP) levels, promoting tumour growth, invasion 
and metastasis [4]. Since tumour angiogenesis requires the up-regulation of these 
factors, anti-angiogenic agents have now been developed. A multitude of trials have 
investigated the effect of anti-angiogenic agents on the progression of cancer as well 
as combination therapies to improve the current standard of care. However, not all 





Signalling from VEGFR2. The signalling cascades downstream of VEGFR2 have been the best studied and are 
illustrated here. VEGF binding to VEGFR2 induces dimerisation of VEGFR2 and phosphorylation of tyrosine 
residues (indicated by the four-digit numbers in the illustration). Pathways activated include the Ras-Raf-
MEK-ERK pathway, PLCγ/PKC pathway and the PI3K/Akt pathway. Activation of downstream signalling 
from VEGF receptors exerts control over multiple processes required for angiogenesis including endothelial cell 
proliferation, migration, tube formation and vascular permeability.
2. The role of VEGF in tumour angiogenesis
Angiogenesis is considered to be a fundamental event in tumour progression 
and metastatic dissemination and is [2] regulated by numerous endogenous factors 
that stimulate or inhibit neovascularisation [3]. One of the most studied pathways is 
the vascular endothelial growth factor (VEGF) family of ligands and their recep-
tors [5]. In humans and mice, the VEGF family consists of 5 members: VEGF-A, 
-B, -C, -D and placental growth factor (PIGF). These ligands demonstrate variable 
specificity for the three VEGF receptors (VEGFR1, VEGFR2, VEGFR3) [3, 5]. The 
predominant member of the VEGF family involved in tumourigenesis is VEGF-A 
and will be referred to as simply ‘VEGF’ from herein.
One of the most important stimuli for tumour angiogenesis is hypoxia, which can 
occur when a rapidly growing tumour exceeds the ability of the local vasculature to 
supply its needs. Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription 
factor, made up of two DNA binding proteins (HIF-1 α and HIF-1 β ), which induces 
the transcription of many genes, including VEGF [6]. In the presence of adequate 
oxygen concentrations, HIF-1 α is ubiquitinated and subsequently degraded by the 
proteasome. However, under hypoxic conditions, HIF-1 α is stabilised and persis-
tently dimerises with the other subunit, HIF-1 β , to form the HIF-1 heterodimer. 
The stabilised HIF-1 is then able to bind the VEGF promoter, leading to persistent 
transcription of the VEGF gene [7]. The expression of VEGF is also stimulated by 
oncogenes, including Ras, c-Src, Bcr-Abl and p53 [8]. A multitude of studies have 
shown that VEGF is overexpressed in the majority of solid tumours and that it is a 
key driver of sprouting angiogenesis [9]. Furthermore, it has been demonstrated in 
multiple xenograft models that VEGF inhibition supresses tumour growth [10].
3. Signalling in the VEGF pathway
Binding of VEGF to the extracellular domain of VEGFR2 causes receptor 
dimerisation and phosphorylation of the receptor on tyrosine residues within the 
3DOI: http://dx.doi.org/10.5772/intechopen.89667
Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy
intracellular domain (Figure 1) [11]. The Y1054 and Y1059 residues, which lie 
within the kinase domain, become phosphorylated in response to VEGF stimula-
tion. These positively regulate the intrinsic kinase activity of the intracellular 
domain and signal to phospholipase-Cγ (PLCγ), which in turn leads to VEGFR2 
internalisation [12]. The Y1175 and Y1214 residues lie in the carboxyl terminal 
tail. These residues become highly phosphorylated in response to VEGF. Y1214 
signalling leads to endothelial cell migration and Y1175 signalling leads to PLCγ 
and extracellular related kinase 1/2 (ERK1/2) activation that is required for DNA 
synthesis and cell proliferation [13]. Activation of ERK1/2 requires the Ras-Raf-
MEK-ERK1/2 signalling cascade but may also require the PLCγ/PKC/PKD pathway 
[14]. The roles of Y951 and Y996 residues, which lie in the kinase insert region, have 
not been definitively determined, but Y951 phosphorylation has been shown to 
increase endothelial cell migration and proliferation via both the PLC-γ and PI3K 
pathways [15].
4. Sprouting angiogenesis
According to the established dogma, VEGF released by tumours stimulates 
the growth of new vessels in the following way. The VEGF diffuses through 
the tissue and activates endothelial cells located in local blood vessels. Firstly, 
VEGF receptor activation induces the selection of sprouting endothelial cells. 
Proteinases such as urokinase-type plasminogen activator, uPA, and members 
of the matrix metalloproteinase (MMP) family mediates the dissolution of the 
vascular basement membrane and extracellular matrix to facilitate the infil-
tration of sprouting endothelial cells into the surrounding tissue [16]. Next, 
endothelial proliferation, migration and branching allows for the formation 
of new vessels. This is followed by sprout fusion and lumen formation where 
vessels fuse together to form a network. Finally, there is perfusion and matura-
tion. This is where the stabilisation of new blood vessels forms a functionally 
perfused system, which is mediated by the recruitment of pericytes to sur-
round the newly formed endothelial tubes; recruitment of pericytes prevents 
further endothelial cell proliferation and migration and also suppresses vessel 
leakage [17].
5. VEGF immunomodulation
Multiple possible mechanisms exist regarding immunosuppressive effects of 
VEGF on the tumour microenvironment. Firstly, due to the effect of VEGF on 
tumour vasculature, T cell migration from lymph nodes to the microenvironment 
may be impaired. Furthermore, the ability of T cells to migrate through vessels is 
negatively affected by VEGF through the down regulation of vascular endothelial 
selectins, adhesion molecules and promotion of Fas ligand expression. Secondly, 
VEGF binding to its receptor on myeloid derived suppressor cells within the tumour 
microenvironment results in STAT 3 signalling, with subsequent promotion of Treg 
cells and the down regulation of tumour specific T cells [18]. Additionally, the bind-
ing of VEGF to VEGFR2 has effects including reduced activation of cytotoxic CD8+ 
and CD4+ T cells, as well as the upregulation of inhibitory receptors including PD1 
and CTLA4 [19]. The interaction of VEGF with VEGFR may also upregulate the 
programmed death ligand 1 (PDL1) on dendritic cells (DCs) [20]. Furthermore, the 




6. The development of anti-angiogenic therapies
Given the key role VEGF is proposed to play in tumour angiogenesis, it is unsur-
prising that it has become a major drug target. Various drugs designed to inhibit 
VEGF signalling have been developed, including VEGF neutralising antibodies  
(e.g. bevacizumab), novel fusion proteins which bind pro-angiogenic growth factors 
(e.g. aflibercept) and VEGF receptor tyrosine kinase inhibitors (e.g. sunitinib) [5, 21]. 
Such agents have shown promise in the treatment of several malignancies, including 
mCRC, metastatic renal cell carcinoma (mRCC), metastatic lung cancer, hepatocel-
lular carcinoma (HCC) and pancreatic neuroendocrine tumours (PNET) [22].
6.1 Bevacizumab
Bevacizumab (Avastin®) is a recombinant humanised monoclonal antibody that 
binds to the VEGF-A isoform of human VEGF specifically and prevents the VEGF 
from activating the VEGF receptor [23].
6.1.1 Bevacizumab in metastatic CRC
Trials with bevacizumab as a single agent in metastatic colorectal cancer 
(mCRC) failed to demonstrate activity, but early Phase I trials demonstrated that 
it has the potential to be combined with many chemotherapy agents [24]. In the 
advanced setting, several randomised Phase II and III clinical trials clearly demon-
strated that bevacizumab improves response rates (ORR), progression free survival 
(PFS) and overall survival (OS) in mCRC, when added to standard chemotherapy 
in the first line setting [25, 26], and the second line setting [27] (Table 1). In 
February 2004, the US Food and Drug Administration (FDA) approved beva-
cizumab for the treatment of mCRC in combination with 5-fluorouracil-based 
chemotherapy regimens based on a pivotal Phase III study which demonstrated 
significant PFS and OS survival benefit [25]. Of clinical importance, bevacizumab 
in combination with a fluoropyrimidine has also demonstrated efficacy in elderly 
patients with mCRC [26].
Despite these data, only a small proportion of patients benefit from the addi-
tion of bevacizumab, and furthermore, some studies have demonstrated only an 
increase in PFS, with no increase in ORR or OS (Table 1) [28]. Additionally, even 
those who respond initially to bevacizumab combined with chemotherapy will 
inevitably develop resistance and relapse [29].
In the setting of colorectal liver-only metastasis (CRLM), it has been well demon-
strated that preoperative chemotherapy improves outcome and metastatectomy rates 
[30]. With this in mind, and on the basis that bevacizumab can improve ORR, several 
groups set out to evaluate its role in the preoperative CRLM setting. Findings from a 
small non-randomised controlled trial of neoadjuvant conventional chemotherapy 
with bevacizumab in high-risk CRLM patients alluded to an improvement of CRC 
liver metastasis rate to 40% [31]. Data from retrospective, inter-trial studies have also 
suggested that the addition of bevacizumab to chemotherapy significantly improves 
pathological response in CRLM compared to when chemotherapy is administered 
alone [32]. Subgroup post hoc analyses extracted from large randomised controlled 
trials of unselected patients have failed to show significant improvements in resection 
rates with the addition of bevacizumab [33]. Without prospective randomised trials 
however, it is difficult to make conclusions regarding the efficacy of chemotherapy 
versus chemotherapy combined with bevacizumab in the CRLM setting.
The role of continuing bevacizumab beyond first progression in advanced 
colorectal cancer has also been examined. The results of two non-randomised 
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observational cohort studies (BRiTE and ARIES) demonstrated a significant 
correlation between the use of bevacizumab beyond progression and substantial 
improvement in OS [34, 35]. Benefit of treatment beyond progression following 
first line treatment was later confirmed in a prospective randomised trial [36].
The efficacy of bevacizumab has also been evaluated in the adjuvant setting in 
CRC patients. Two large randomised studies compared survival between the follow-
ing arms: adjuvant chemotherapy alone for 6 months versus adjuvant chemotherapy 
in combination with bevacizumab for 6 months (followed by bevacizumab alone 
for 6 months). Both studies demonstrated that at 1 year there was an improvement 
in PFS in the bevacizumab arm. However, no significant difference in OS was 
observed between treatment arms when assessed at 3 or 5 years [37, 38]. In fact, an 
analysis at 5 years in the AVANT study demonstrated a possible detrimental effect 
on survival with the addition of bevacizumab, documenting a higher number of 
relapses and deaths due to disease progression [37].
6.1.2 Bevacizumab in other tumour types
Bevacizumab in combination with cytotoxic chemotherapy has also shown 
significant clinical efficacy in other tumour types.
In advanced non-squamous non-small cell lung cancer (NSCLC), two randomised 
controlled phase III trials demonstrated significant benefit in PFS when bevacizumab 
was added to platinum-based doublet chemotherapy [39, 40], but only one study 
reported an increase in OS [40]. To further understand this discrepancy, a recent meta-
analysis pooling data from several studies including the aforementioned two, deduced 
a modest but significant improvement in OS [41]. More recently in metastatic non-
squamous NSCLC, the Impower150 phase 3 clinical trial investigated treatment with 
Table 1. 
Studies investigating bevacizumab in metastatic colorectal cancer in the first line.
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bevacizumab plus platinum doublet chemotherapy with or without the PDL1 inhibitor 
atezolizumab. Treatment with atezolizumab, bevacizumab and chemotherapy com-
pared with bevacizumab and chemotherapy resulted in a significant improvement 
in PFS at 6 months (66.9% vs. 36.5%) and at 12 months (56.1% vs. 18%) [42]. In an 
interim analysis of OS, an improvement was again seen (Table 2) [42].
In advanced ovarian cancer, in the first- and second-line settings, the efficacy 
of bevacizumab has been assessed when added to platinum-based chemotherapy 
doublets. Two pivotal first line phase III studies utilising the same chemotherapy 
doublet (ICON7/AGO-OVAR and GOG-0218 trials) demonstrated a significant 
improvement in PFS [43]. An updated survival analysis failed to show a significant 
survival benefit [43].
Bevacizumab has been investigated in glioblastoma multiforme (GBM), in the 
recurrent setting following first line treatment with temozolamide and radia-
tion therapy. In this setting bevacizumab monotherapy is ineffective, however 
in combination with lomustine it has resulted in improvement in PFS but not OS 
[44]. Bevacizumab has also been investigated in the first line setting with chemo-
radiation in a large randomised placebo controlled trial, but failed to improve 
outcomes [45].
Earlier phase III trials in RCC have demonstrated efficacy of bevacizumab 
in combination with sorafenib, sunitinib and interferon alpha (Table 2). More 
recently, bevacizumab has been combined with atezolizumab in metastatic RCC. A 
phase III randomised trial confirmed significant improvement in PFS for bevaci-
zumab combined with atezolizumab compared with sunitinib monotherapy but 
mature OS data are still awaited [46].
Despite such encouraging results, bevacizumab has thus far failed to make a 
significant impact in several other indications, including metastatic breast cancer 
(mBC), melanoma, pancreatic cancer and prostate cancer. Interestingly, in breast 
cancer, pooled data from four large clinical trials demonstrated that it neither pro-
longed OS, nor delayed disease progression significantly, leading the FDA to revoke 
its initial approval of bevacizumab for mBC [47]. The variation in impact that 
bevacizumab has, not only across tumour types, but also within a single tumour 
type, is curious and needs to be better understood.
6.2 Ramucirumab
Ramucirumab is a fully human IgG1 monoclonal antibody that binds to the 
extracellular domain of VEGFR-2, blocking VEGF from activating the receptor [48]. 
Clinical efficacy and tolerability have been demonstrated in a number of preclini-
cal studies and more recently in phase III trials. In the refractory metastatic gastric 
and gastro-oesophageal junction (GOJ) adenocarcinoma setting, ramucirumab 
significantly improved median OS compared with placebo but this only represented 
an absolute improvement of 1.4 months [49]. In the second line setting of advanced 
gastric and GOJ adenocarcinoma, the combination of ramucirumab and paclitaxel 
has become standard treatment based on the results of the pivotal RAINBOW trial 
showing significant improvement in OS compared with paclitaxel and placebo [50]. 
Ramucirumab has not shown benefit in the first line setting including combination 
with chemotherapy [51].
Ramucirumab has also been investigated in metastatic NSCLC but does not yet 
have an established role for this indication. After progression on first line platinum 
based chemotherapy, there was a small but statistically significant benefit in median 
OS of ramucirumab added to docetaxel [52]. Early results of the RELAY phase 3 
clinical trial investigating ramucirumab in combination with erlotinib in the first 
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line setting of metastatic EGFR mutated NSCLC have indicated an improvement in 
PFS however formal publication of the study findings are awaited.
Ramucirumab has also been investigated in urothelial cancers. In a phase III trial 
of ramucirumab plus docetaxel compared with docetaxel plus placebo in patients 
with advanced urothelial carcinoma who had received platinum-based chemother-
apy, there was a statistically significant improvement in median PFS (4.07 months 
vs. 2.76 months) [53].
Table 2. 




Aflibercept is a recombinant fusion protein that binds to VEGF-A, VEGF-B and 
placental growth factor (PLGF), all of which have been implicated in angiogenesis 
and/or the survival of newly formed blood vessels [54]. As it binds to additional 
pro-angiogenic targets (compared to bevacizumab which binds only VEGF-A), 
aflibercept may provide further anti-angiogenic effects compared to targeting 
VEGF-A alone. In preclinical studies, it demonstrated a broad range of anti-tumour 
and anti-angiogenic activity both alone and in combination with chemotherapy, 
which was also observed in phase I clinical trials [55]. Recently, a large randomised 
phase III clinical trial (VELOUR) in advanced CRC patients, receiving second line 
therapy, demonstrated that the addition of aflibercept to systemic chemotherapy 
significantly improved outcomes compared to chemotherapy alone [56]. Based on 
this data, aflibercept was recently approved for use in the second line setting in 
mCRC when given in combination with chemotherapy. Importantly, results from 
a subanalysis of VELOUR showed that there was no significant impact of prior 
exposure to bevacizumab, illustrating the benefit that it provides as a multiple 
angiogenic factor trap, in a setting where resistance to bevacizumab may have 
developed [57].
6.4 Receptor tyrosine kinase inhibitors (TKIs)
Several small molecule inhibitors of VEGF receptor tyrosine kinase activity now 
have an established role in the treatment of certain tumour types, including mRCC, 
HCC and advanced CRC. These small molecule inhibitors readily diffuse through 
the cell membrane to compete for ATP binding to the intracellular tyrosine kinase 
domain of VEGF receptor 2.
6.4.1 Sunitinib
Sunitinib is an orally active multi-kinase inhibitor, which targets VEGFR1–3, 
PDGFR α / β , c-Kit and FLT3 [58]. Xenograft models have clearly demonstrated that 
as well as inhibiting new blood vessel formation, sunitinib also induces regression 
of newly formed immature vessels and significantly stunts tumour growth [59]. 
Furthermore, immunohistochemical studies performed on human tissue derived 
from mRCC patients treated with sunitinib have demonstrated that this agent can 
induce a reduction in tumour vessel density [60].
In terms of outcome in the clinical setting, sunitinib initially showed efficacy, 
as a single agent, for second-line therapy in single-arm, Phase II studies in mRCC 
[61]. Patients treated with sunitinib showed promising outcomes in terms of ORR, 
response duration, PFS and OS. A pivotal Phase III study was subsequently con-
ducted comparing sunitinib with interferon-α as a first-line treatment in mRCC, 
which demonstrated improved OS, PFS and ORR in the sunitinib arm [62]. Based 
on such data, sunitinib was approved by the FDA in 2006 for the first line treat-
ment of mRCC. Other TKI’s, with similar target specificity (sorafenib, pazopanib, 
cabozantinib and axitinib) also have activity in mRCC. Combination with immuno-
therapeutic agents has also shown promising results and we are seeing the treatment 
algorithm for mRCC change rapidly. In a recent landmark phase 3 trial of advanced 
RCC in the first line setting, axitinib was combined with the PD1 inihibitor pembro-
lizumab and compared with sunitinib monotherapy (KEYNOTE-426). The results 
are promising with a significant improvement in PFS and ORR with axitinib and 
pembrolizumab, however more mature OS data are awaited [63].
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The role of such TKIs has also being evaluated in mCRC. The anti-tumour and 
anti-angiogenic effects of sunitinib have been well documented in a series of CRC 
xenograft tumour models [64]. In the clinical setting, however, sunitinib employed 
either as a single agent or with combination chemotherapy, has failed to demon-
strate favourable outcome, both for ORR and PFS [65].
6.4.2 Regorafenib
Recently, another TKI called regorafenib has created a lot of interest in advanced 
CRC. This agent inhibits VEGFR1-3, PDGFR α / β , KIT, RET, FGFR1 and Tie2. It is 
also a potent inhibitor of Raf-1 and suppresses both wild-type and V599E mutant 
BRAF activity in vitro and in mouse models [66]. Significant anti-tumour and 
anti-angiogenic effects in CRC xenograft models, both as a single agent and in 
combination with irinotecan chemotherapy have been reported [67]. In the clinical 
setting, the Phase III CORRECT trial demonstrated significant benefit for OS and 
PFS in advanced CRC patients, when it was used as a single agent compared to best 
supportive care, in a population who had failed previous standard therapy [68]. 
Based on this data, regorafenib was approved by the FDA as a multikinase inhibitor 
for metastatic colorectal cancer in the third line setting in 2012.
Regorafenib also has clinical utility in gastrointestinal stromal tumours (GIST) 
where it is currently employed in the third line setting after imatinib and suni-
tinib. This indication followed from a phase 3 randomised trial, demonstrating 
significantly improved PFS for regorafenib compared with placebo (4.8 months vs. 
0.9 months) [69]. There was no significant difference in OS, however this trial did 
allow for crossover which likely impacted on this finding [69].
Regorafenib has FDA approval for second line treatment of HCC following the 
positive results of the phase 3 RESORCE clinical trial. Compared with placebo, 
regorafenib demonstrated survival benefit [70].
7.  Potential mechanisms of synergy between bevacizumab and 
chemotherapy
Early phase clinical trials have demonstrated that bevacizumab, in combination 
with systemic cytotoxic chemotherapy, can potentiate treatment efficacy when 
given concomitantly [71]. In fact, in most clinical settings, with the exception of 
ovarian cancer where bevacizumab has been observed to have single agent activity 
[72], bevacizumab has only shown significant activity when it is combined with 
cytotoxic chemotherapy and the same is true for aflibercept [21].
It has been well-established that the tumour vasculature is dysfunctional and 
leaky, resulting in enhanced interstitial fluid pressure and thus preventing effec-
tive delivery of chemotherapy [73]. Evidence from preclinical studies showed that 
bevacizumab can ‘normalise’ the chaotic tumour vasculature, achieving reduced 
vessel tortuosity, reduced leakiness and reduced interstitial fluid pressure. Based on 
these studies, it was proposed that bevacizumab works in combination with chemo-
therapy to improve chemotherapy delivery [71, 73], which is now a widely accepted 
notion amongst many clinicians.
However, this concept is also highly controversial, with some work even refuting 
the normalisation hypothesis. For example, one group demonstrated that bevaci-
zumab persistently reduced both tumour perfusion and chemotherapy delivery 
when NSCLC patients were treated with bevacizumab-containing chemotherapy 
[74]. Therefore, other potential explanations for synergy between bevacizumab and 
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chemotherapy must be considered. Current alternative theories based mostly on 
preclinical data include: (1) direct synergy between the anti-angiogenic effects of 
bevacizumab and potential anti-angiogenic effects of chemotherapy [75], (2) tar-
geting of VEGF signalling directly in cancer cells by bevacizumab [21], (3) chemo-
therapy may inhibit resistance to bevacizumab, because chemotherapy suppresses 
the tumour recruitment of myeloid cells that have been implicated in resistance to 
bevacizumab [76], (4) bevacizumab may prevent tumour rebound that may occur 
during breaks in chemotherapy [76].
It should be noted that vessel normalisation facilitated by anti-angiogenic agents 
may provide therapeutic benefit through other mechanisms, which are independent 
of chemotherapy delivery. For example, in glioblastoma patients, vessel normalisa-
tion induced by single agent VEGF-targeted therapy may prolong survival due to 
other effects, such as oedema control or improved tumour oxygenation [77].
There are two other curious observations that have yet to be properly explained. 
Firstly, the synergistic effect of adding bevacizumab to chemotherapy does not occur in 
all tumour types. For example, the addition of bevacizumab does not lead to improve-
ments in outcome in advanced breast cancer [78]. Secondly, VEGFR TKIs show single 
agent activity without the need for co-administration of chemotherapy [21].
Recent insight into these two curious observations has been reported. A study 
examining both clinical and mouse tumour tissue specimens demonstrated that 
tumour types utilising a vasculature surrounded by a well-developed stroma (e.g. 
mCRC, NSCLC) respond better to bevacizumab when it is added to chemotherapy 
as opposed to tumour types that utilise a vasculature without a well-developed 
intervening stromal component (e.g. mRCC, PNET) which respond better to VEGF 
TKIs alone [79]. This suggests that tumour cell interactions with different stromal 
components may influence response to different anti-angiogenic agents and how 
they synergise with concomitant drugs. However, there is still much work to be 
done in order to understand the mechanisms involved.
8. Synergy of anti-angiogenic agents with immunomodulatory therapy
A series of pre-clinical studies have shown that the use of anti-angiogenic agents 
along with immune checkpoint inhibitors (ICI) as a combination therapy has a syn-
ergistic and enhanced effect on the tumour when compared to either ICI therapy 
or anti-angiogenic therapy alone. Immunotherapy has emerged as a promising 
treatment option for many cancer types, offering hope for patients with the demon-
stration of improved outcomes including durable responses in some. Unfortunately, 
there are still many patients that either have short lived responses to such therapies 
or none at all. To overcome resistance mechanisms, combinations of immunother-
apy with other treatments including VEGF inhibitors are being explored.
Since 2013, pre-clinical investigations in mice with various tumours have indi-
cated that the combination of ICI and anti-angiogenic agents results in prolonged 
overall survival [80]. It has been observed that the VEGF can cause the upregulation 
of immune checkpoint molecules such as PD-1 and as a result, the use of anti-VEGF 
agents has been seen to reduce the expression of PD-1 on cytotoxic T lymphocytes 
[81]. Thus, the combination of using both anti-VEGF agents as well as anti-PD-1 
agents could have a synergistic effect on inhibiting further tumour development 
[81]. Through the encouraging findings of pre-clinical investigations, many clinical 
studies have recently or are still in the process of investigating this.
There are a multitude of clinical studies supporting the role of bevacizumab 
in the positive immune modulation of the tumour microenvironment and its 
beneficial effects when combined with the immune checkpoint PD1/PDL1 and 
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CTLA4 inhibitors. In a study investigating melanoma patients treated with ipili-
mumab plus bevacizumab versus ipilimumab alone, the results showed that the 
combination therapy increased circulating CD4+ and CD8+ T cells compared with 
ipilimumab monotherapy [82]. The investigation showed that there was a greater 
median overall survival in patients undergoing combination therapy (25.1 months) 
compared to those who underwent the ipilimumab alone treatment (10.1 months) 
[82]. Furthermore, a separate study of patients with RCC investigating the effect 
that bevacizumab plus atezolizumab had versus bevacizumab alone found that 
the combination therapy demonstrated a reduction in neovasulature-related gene 
expression and decreased microvascular density. The treatment was also associated 
with an increased tumour infiltration of CD8+ T cells as demonstrated by immuno-
histochemical staining of cells [83]. This study also demonstrated that MHC Class I 
is upregulated as a result of the treatment and that both intratumoural CD8+ T cells 
and macrophages increased as well.
In a phase II study involving patients with RCC, as compared with sunitinib 
monotherapy, atezolizumab and bevacizumab demonstrated improvements in PFS 
in patients with an immunosuppressive tumour microenvironment [84]. Whilst it 
was also discovered that the use of atezolizumab failed to generate an anti-tumour 
immune response (possibly due to myeloid-induced immune suppression), the 
addition of bevacizumab to atezolizumab was found to be able to overcome this 
suppression [84].
Both pre-clinical and clinical studies have shown that anti-angiogenic agents and 
immunomodulatory therapies have a synergistic affect in reducing tumour growth 
and a multitude of clinical trials are currently investigating this synergy further. 
Thus, there is promise in the use of a combination therapy with anti-angiogenic 
agents and immunomodulatory agents to improve on patient prognosis.
9. Potential predictive biomarkers for anti-angiogenic agents
In view of the variable outcomes seen in the clinic, there is a need for the devel-
opment of validated predictive biomarkers of response for anti-angiogenic therapy. 
In this way, patients who will derive benefit from such agents could be appropriately 
selected, whilst those that will not derive benefit (either at the outset or during 
therapy) could be selected for alternative, more effective therapy. Such a strategy 
would not only improve clinical outcomes but would also reduce the unnecessary 
burden of (a) toxicity to the patient, and (b) cost to the economy. Despite extensive 
international research in this field, there is currently no biomarker which predicts 
benefit or resistance to anti-angiogenic agents that is approved for routine clinical 
practice. The following are amongst several which have been investigated in the 
clinical setting.
9.1 Circulating biomarkers
Circulating biomarkers are an attractive tool for patients and clinicians as 
‘liquid biopsies’ are relatively non-invasive and easy to perform, as compared with 
tissue biopsies of tumour with associated risks and potential technical difficulties 
depending on tumour site. VEGF levels have been studied as a potential biomarker 
with high levels associated with poorer outcomes [85]. Findings regarding its utility 
as a predictive biomarker have been more inconsistent [85]. An analysis of four 
randomised phase 3 trials investigated circulating VEGF level as a prognostic and 
predictive biomarker in mCRC, lung cancer and RCC which included bevacizumab 
in the treatment regimen. Tumour specimens were also tested for VEGF level. This 
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found that higher baseline circulating VEGF levels were associated with poorer 
clinical outcomes but levels did not predict response to bevacizumab [86]. There is 
early evidence from small and exploratory studies to suggest soluble VEGFR-1, with 
higher levels being associated with poorer outcomes with anti-angiogenic treat-
ments, however larger studies are required to confirm these findings [87].
Other potential circulating biomarkers have also been investigated. In mCRC, 
elevated IL-8 levels at baseline were associated with a shorter PFS in patients 
treated with chemotherapy (FOLFIRI) and bevacizumab [88]. Elevated LDH and 
neutrophil levels have been found to independently predict poorer survival in 
patients treated with chemotherapy plus bevacizumab [89]. A promising predictive 
biomarker for response to bevacizumab based therapy in CRC appears to be circu-
lating endothelial cells, with studies showing that patients with lower circulating 
endothelial cells at baseline undergoing treatment with bevacizumab based therapy 
had improved PFS [90].
9.2 Levels of tumour VEGF isoforms
Levels of VEGF expression in a tumour could be a determinant of responsive-
ness to anti-VEGF therapy. Some small studies have demonstrated a relationship 
between baseline VEGF expression and response, however these findings have not 
been consistently replicated in large clinical trials and are often more informa-
tive as prognostic rather than predictive biomarkers [91]. Data from more recent 
prospective studies, however, have shown more consistency in the use of VEGF as a 
biomarker. A large randomised trial in patients with advanced breast cancer treated 
with bevacizumab demonstrated a significant association between high circulating 
levels of VEGF and survival benefit [78]. VEGF expression in tumours was inves-
tigated in the large phase III clinical trial of bevacizumab plus chemotherapy in 
mCRC, but this failed to predict outcomes [92].
There are multiple reasons why using VEGF expression as a biomarker could be 
problematic: (1) advanced tumours express numerous pro-angiogenic factors in 
addition to VEGF which could confer resistance to bevacizumab irrespective of the 
amount of VEGF produced [93], (2) differences in the intensity of VEGF expression 
might be too small to be clinically relevant, (3) hypoxia, which is promoted by anti-
angiogenic therapy, is an important inducer of VEGF expression and might, there-
fore, lead to increased VEGF production in the presence of bevacizumab treatment; 
indeed, anti-angiogenic agents have been shown to induce expression of VEGF even 
in tumour naïve hosts [94], (4) variations in methodology across centres (including 
sample handling, the use of different scoring systems and non-validated antibod-
ies) have a significant effect on biomarker trial results [95], (5) it is very challenging 
to standardise cut-offs for low and high VEGF levels, due to: (a) different methods 
used to measure VEGF at different centres and (b) differences in biology that occur 
between racial groups, tumour types and different stages of disease [95].
9.3 Levels of alternative pro-angiogenic growth factors
Studies which have investigated other single circulating factors (such as FGF2, 
and r soluble VEGFR2) have also yielded contradictory and unsatisfactory conclu-
sions [96]. Interestingly, however, recent clinical work in mRCC patients treated 
with anti-angiogenic TKIs suggests that profiling multiple circulating factors in the 
blood could have a more powerful prognostic and predictive role than assessing lev-
els of single factors alone [97]. In this study, when patients with mRCC were treated 
with the TKI pazopanib, a biomarker signature of six factors (HGF, interleukin 6 and 
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interleukin 8, osteopontin, VEGF and TIMP1) was able to distinguish a sub-group of 
patients that derived a significantly greater overall survival benefit from this agent.
9.4 VEGF polymorphisms
Polymorphisms in VEGF or VEGF receptors have been proposed to predict out-
come from anti-angiogenic therapy. As these are generally binary in nature, they are 
attractive biomarkers since they may be easier to measure and apply prospectively. 
In metastatic breast cancer, polymorphisms in VEGF and VEGFR2 were analysed in 
several retrospective subset analyses in patients treated with chemotherapy, with or 
without bevacizumab. Two polymorphisms within the VEGF promoter/5′ untrans-
lated region, VEGF alleles −2578AA and −1154AA, were significantly associated 
with improved OS in the bevacizumab plus paclitaxel group when compared to the 
−2578CA/−2578CC and −1154GA/−1154GG alleles. In contrast, they did not have 
prognostic power for OS in the chemotherapy-only arm [98]. The predictive power 
of the −2578AA and −1154AA VEGF alleles was also reported in a retrospective 
subset analysis of patients with metastatic colorectal cancer that received either 
FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus bevacizumab or XELIRI 
(capecitabine and irinotecan) plus bevacizumab [99].
More recently, the role of VEGFR1 polymorphisms was studied in a large 
meta-analysis pooling DNA data from two phase III trials in patients with advanced 
pancreatic cancer treated with bevacizumab. VEGFR1 −1213AC/−1213CC alleles 
were significantly associated with poor outcome in patients receiving bevacizumab 
when compared to VEGFR1 −1213AA alleles [100]. To understand how this VEGFR1 
polymorphism functionally affects VEGFR1 expression and how it might explain 
its correlation with poor outcome in patients receiving bevacizumab, Lambrechts 
and colleagues performed an in vitro study where the mutant codon of Tyr1213 was 
transiently overexpressed in HEK293T cells. Lysates from these cells demonstrated a 
significant increase in expression and signalling of VEGFR1 compared to HEK293T 
cells harbouring the wild type codon, thus providing a biological rationale for the 
role of this polymorphism as a negative predictive marker of response [100]. A sig-
nificant correlation of the VEGFR −1213 with poor outcome was also corroborated 
by a subsequent study in patients with mRCC treated with sunitinib [101].
9.5 Radiological parameters
Functional clinical imaging, taking into account tumour vasculature or 
metabolic activity by utilising CT, MRI or PET scanning, either prior to com-
mencing treatment or following brief exposure of patients to therapy, may be a 
useful tool for predicting response or resistance to anti-angiogenic therapy [102]. 
For conventional cytotoxic chemotherapy, imaging has been employed to assess 
therapy response based on change in tumour size, as defined by RECIST (Response 
Evaluation Criteria In Solid Tumours). However, biological agents, such as bevaci-
zumab and TKIs, may be cytostatic in terms of their mechanism of action, thus size 
may not be the only parameter that needs to be considered when assessing response 
and outcome. Examination of various parameters such as blood flow and tumour 
morphology may provide additional important predictive information.
9.5.1 Baseline vascular perfusion on imaging
Several studies have examined pre-treatment levels of tumour perfusion and 
whether they can predict outcome. For example, enhanced levels of vessel perfusion 
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at baseline (measured by contrast-assisted tumour enhancement) in mRCC patients 
treated with VEGF TKIs has been shown to predict for response and survival [103].
9.5.2 Changes in vascular characteristics on imaging
Early alterations in features of the tumour vasculature on imaging after a short 
period of therapy have also been shown to be associated with response and out-
come. For example, in studies of mRCC patients treated with anti-angiogenic TKIs, 
response criteria that measured both a significant reduction in tumour vascular per-
fusion and a significant reduction in tumour size were more predictive of outcome 
compared to change in lesion size alone [104].
Although the use of the above radiological criteria may seem promising as 
predictors of response and outcome, there are associated challenges that need 
to be considered before incorporating them into clinical practice. These include, 
(a) diversity in the methodologies used to assess potential surrogate radiological 
biomarkers of response between studies and across centres, and (b) insufficient 
comprehension of how certain radiological features correlate with the underlying 
tumour biology.
10. Measuring the clinical response to anti-angiogenic agents
Currently, the efficacy of any anti-neoplastic therapy is assessed by several 
outcome measures, which include (a) effective downsizing of tumours on clinical 
imaging (to facilitate curative surgery or consolidative radiotherapy for localised 
disease and to reduce the symptomatic burden of disease in the metastatic setting), 
(b) prolongation of the interval where a patient is either disease-free or progres-
sion-free, and (c) prolongation of survival.
Conventional assessment of residual tumour volume after cytotoxic chemo-
therapy has traditionally been performed with the use of size-based criteria (overall 
response rate, ORR, by RECIST). This was based on evidence that there is good cor-
relation between radiological information and residual viable tumour (pathological 
response) and good correlation with progression-free (PFS) and overall survival 
(OS) in patients treated with cytotoxic chemotherapy [105]. However, with the 
advent of biological therapies, such as bevacizumab, the value of utilising RECIST 
on its own as a surrogate for outcome has been questioned and new imaging criteria 
have been proposed [102].
10.1 RECIST criteria
For anti-angiogenic therapy employed in advanced malignant disease, retro-
spective clinical meta-analyses have (a) highlighted the pitfalls and limitations 
of using RECIST alone in the assessment of response and progression, and (b) 
highlighted a disassociation of RECIST from time-related endpoints of PFS and 
OS [105].
This curiosity was provoked by several large randomised clinical trials investigating 
the effect of adding bevacizumab to conventional chemotherapy in different tumour 
types. These have consistently demonstrated that significant improvements in PFS and 
OS were incongruent with modest increases in ORRs [25, 28, 40]. In their CRC meta-
analysis, Grothey and colleagues specifically examined the impact of tumour response 
to bevacizumab (ORR) on treatment benefit (PFS, OS) and concluded that patients 
who did not attain a positive response according to RECIST (i.e. stable disease) in fact 
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showed significant benefit from bevacizumab, which was of the same magnitude as 
responding patients (i.e. complete or partial response) [105].
Moreover, similar concepts have consistently featured in several Phase I and II 
clinical trials employing antiangiogenic agents, and other molecular targeted thera-
pies. These studies corroborate that there is little value in utilising ORR alone, par-
ticularly in predicting whether an agent will ultimately have truly meaningful effects 
on pathological response or in prolonging survival [106]. The underlying reason for 
these incongruent observations with bevacizumab and other molecular targeted 
therapies may be because such agents are cytostatic rather than cytotoxic [107].
10.2 Morphological response criteria
There has been growing interest in how the appearance of lesions on clinical 
imaging can be utilised to accurately assess the effect of bevacizumab on tumour 
volume and how this appearance may correlate with other clinical end-points. 
In a small retrospective colorectal liver only metastasis (CRLM) patient cohort 
treated with bevacizumab and chemotherapy, Chun and colleagues demonstrated 
that novel morphological response criteria predicted more accurately for OS 
and pathological response than RECIST (Figure 2) [108]. This was subsequently 
validated in a larger patient population which included patients who were treated 
with and without bevacizumab [109]. Not only were the morphological response 
criteria superior to RECIST in predicting major pathological response and OS, 
further analyses confirmed that the morphological response criteria did not 
correlate with responses measured according to RECIST. Moreover, there was a 
significantly higher incidence of optimal responses (measured by morphological 
response criteria) in the patient cohort receiving bevacizumab with chemo-
therapy compared to the chemotherapy alone cohort [109]. These data suggest 
that (a) morphological response criteria and RECIST measure different biological 
parameters, and (b) the use of morphological response criteria represents a more 
sensitive tool for measuring tumour response and time-related endpoints of 
survival for bevacizumab. Similar findings were reported in a retrospective study 
of non-small cell lung cancer patients treated with bevacizumab and concomitant 
chemotherapy [110].
10.3 Pathological response criteria
Radiological assessment alone may not accurately reflect response to therapy 
because simple, unidimensional imaging parameters may overestimate or under-
estimate downstaging of tumour burden [111]. Furthermore, in the case of adding 
anti-angiogenic therapy to chemotherapy, although it has been suggested that 
proposed morphological imaging characteristics can accurately predict tumour 
response and clinical outcome, such scoring methods have not yet been validated 
for conventional use in clinical practice and may also be too subjective. Scoring of 
pathological response may therefore be a better alternative or perhaps an adjunct 
in assessing residual viable tumour. Moreover, in the case of preoperative chemo-
therapy or radiotherapy in settings such as rectal cancer and oesophageal cancer, 
pathological response has also been shown to correlate significantly to disease-free 
survival (DFS) and OS [112].
Several methodologies incorporating various parameters for scoring pathologi-
cal response in resected CRLMs, treated with and without bevacizumab, have been 
proposed. It is still not clear from the current literature which of these classification 
methods may be superior.
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10.3.1 Percentage viable tumour
Microscopic assessment of the percentage residual viable tumour on haematoxy-
lin & eosin-stained sections of resected tissue has been employed as a predominant 
parameter in assessing the efficacy of different pre-operative chemotherapy 
regimens in tumour types such as oesophageal, gastric and rectal adenocarcinomas 
[113]. Based on this methodology, Ribero and colleagues modified this scoring sys-
tem for application in CRLMs treated preoperatively, with or without bevacizumab 
[114]. A semi-quantitative estimation of the percentage area of residual viable 
tumour cells relative to total tumour surface area within each CRLM metastasis 
was made with the analysis of four tumour cell viability subsets (<25%, 25–49%, 
Figure 2. 
Morphological response criteria on contrast-enhanced CT (CECT) scans as a predictor of outcome (i) 
and (ii) CECT performed in a 43-year old patient before and after 10 cycles of bevacizumab containing 
chemotherapy demonstrating an optimal response (OR). (i) Before therapy, the liver metastasis presented 
with profound heterogeneous attenuation, a hyperattenuated peripheral rim and a thick, poorly defined 
tumour-liver interface (‘group 3’ metastasis). (ii) After therapy, the same liver metastasis shows complete 
resolution of these features (i.e. it is homogeneous, of low attenuation, with a thin, sharply defined tumor-liver 
interface). Change in size of lesion is minimal. (iii) and (iv) CECT of the liver performed in a 67-year old 
patient before and after 2 cycles of bevacizumab-containing chemotherapy demonstrating a partial response 
(PR). (iii) Before therapy, the liver metastas is presented with features of a ‘group 3’ metastasis. (iv) After 
therapy, the same liver metastasis shows moderate resolution of these features (i.e. it has a moderate degree 
of heterogeneous attenuation, a moderately defined tumor-liver interface with a slight hyperattenuating 
peripheralrim (‘group 2’ metastasis)). (v) and (vi) CECT of the liver performed in a 56-year old patient before 
and after 2 cycles of bevacizumab-containing chemotherapy demonstrating an absent response (AR). (v) Before 
therapy, the liver metastasis presented with features of a ‘group 3’ metastasis. (vi) After therapy, the same liver 
metastas is shows a decrease in tumour size without change in attenuation or tumour-liver interface (‘group 3’ 
metastasis). Changes in tumour morphology on CECT have been shown to correlate more significantly 
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50–75%, >75%). This retrospective study confirmed that the addition of bevaci-
zumab to chemotherapy yielded an incrementally greater decrease in residual viable 
cells within these CRLMs in comparison to those treated with chemotherapy alone 
but no correlation with imaging, or other clinical end-points, was made [114].
10.3.2 Tumour regression grade (TRG)
Mandard and colleagues were one of the first to establish a five-point histologi-
cal scoring system for pathological response. This was based on cytological and 
stromal changes on haematoxylin & eosin-stained sections of primary oesophageal 
squamous cell carcinomas treated with chemoradiotherapy prior to resection [115]. 
Figure 3. 
Tumour regression grade (TRG) scoring system as a component of measuring pathological response in treated 
CRLMs. (A–E) TRG as scored on haematoxylin and eosin sections of CRLMs based on the proportion 
of fibrosis to viable tumour cells. The five TRGs shown in this cartoon roughly illustrate the different 
proportions of fibrosis (fibrils) to tumour cells (black areas). (A) TRG1. There is an absence of viable 
tumour cells and large amounts of fibrosis. (B) TRG2. The presence of viable tumour cells is rare and they are 
scattered throughout the fibrosis. (C) TRG3. There is the presence of more residual tumour cells but fibrosis 
predominates. (D) TRG4. Residual cancer cells predominate over fibrosis. (E) TRG5. There are no signs of 
tumour regression. The percentage of the CRLM surface area occupied by necrosis is also incorporated as a 
parameter for pathological response (grey areas). 3 main pathological response groups: TRG1-2: major response 
(MjHR), TRG3: partial response (PHR), TRG4-5: no histological response (NHR).
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Tumour response was scored according to five tumour regression grades (TRG1-5) 
based on the proportion of fibrosis to viable tumour cells. Later, this TRG scoring 
system was modified for its application in CRLMs receiving different chemotherapy 
backbones prior to liver resection (Figure 3A–E) [116]. Correlation analyses have 
demonstrated a significant association of major histological responders with 
increased survival.
Similar retrospective studies using the TRG in CRLMs were undertaken to see 
whether adding bevacizumab to chemotherapy would further increase pathological 
response rate, without necessarily increasing radiographic response rate, after liver 
resection. Indeed, several retrospective analyses demonstrated that a significantly 
increased percentage of patients treated with bevacizumab achieved a major 
pathological response and a significantly higher percentage area of tumour necrosis 
compared to chemotherapy-only treated patients [117]. Furthermore, the extent 
of pathological response correlated significantly with long-term-outcomes such as 
3- and 5-year overall survival.
11. Mechanisms of resistance to anti-VEGF therapy
As is the case with most cancer therapeutics, drug resistance is considered to 
be a major factor that limits the efficacy of anti-angiogenic agents. Two ‘modes’ of 
resistance to anti-angiogenic therapy are currently recognised: intrinsic resistance, 
whereby the tumour fails to respond to the therapy from the outset, and acquired 
resistance, whereby the tumour develops means to evade the therapy after a period 
of response [21, 29, 118]. It is important to realise that resistance to anti-angiogenic 
therapy may be attributable to either the tumour cells themselves or due to interac-
tions with their microenvironment. In terms of specific mechanisms mediating 
resistance to anti-angiogenic therapy, several have been proposed.
11.1 Vessel heterogeneity
Pre-clinical work has demonstrated that although anti-angiogenic agents thwart 
the growth of newly established tumour vessels, they are less effective against 
more mature blood vessels, indicating that they may be less dependent on VEGF 
(Figure 4A) [29]. This may be due to PDGF secretion mediating pericyte recruit-
ment, allowing young vessels to mature and survive [119]. Co-inhibition of VEGF 
and PDGF has been shown to generate significant anti-angiogenic and anti-tumour 
effects than with VEGF inhibition alone [120].
11.2 Alternative pro-angiogenic signalling pathways
Alternative pro-angiogenic signalling pathways may allow tumour vascularisa-
tion to proceed when VEGF signalling is blocked (Figure 4B) [29]. A large body 
of preclinical work has identified candidate pathways that may provide such an 
alternative pro-angiogenic stimulus. These include fibroblast growth factors 1 and 
2 (FGF1 and FGF2) [121], hepatocyte growth factor (HGF) [122] and epidermal 
growth factor (EGF) [123]. Most of the above preclinical work suggests that, by 
inhibiting both VEGF signalling and the candidate pathway, improvements in the 
anti-tumour efficacy can be seen. Therefore, targeting multiple pro-angiogenic 
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11.3 Role of stromal cells
Preclinical data suggest that cells in the tumour stroma, including fibro-
blasts, neutrophils, macrophages and myeloid progenitors, mediate resistance 
to VEGF-targeted agents (Figure 4C) [124]. For example, tumour-derived 
granulocyte-colony stimulating factor (G-CSF) mobilises myeloid cells from bone 
marrow, and is believed to promote pro-angiogenic Bv8 signalling by myeloid 
cells, which in tumours may confer resistance to anti-VEGF treatment [125]. 
Immunohistochemistry studies in human tumours showed expression of Bv8 in 
tumour-infiltrating neutrophils, which were seen in around 15% of breast carcino-
mas [126].
11.4 Tumour cell adaptation to stress
It is presumed that the inhibition of tumour vascularisation by anti-angiogenic 
agents will lead to a reduction in oxygen and nutrients available to the tumour 
thus causing retardation of tumour growth. However, tumours may develop a 
number of survival mechanisms enabling them to adapt to such hostile conditions 
(Figure 4D).
11.4.1 Metabolism
Some studies have suggested that anti-angiogenic therapy leads to metabolic 
reprogramming of tumour cells, allowing them to adapt to reduced vascular supply. 
Preclinical studies have demonstrated that treatment with anti-VEGF antibod-
ies can lead to tumour cells relying on anaerobic metabolism and the glycolytic 
pathway for ATP [127]. Furthermore, the withdrawal of anti-angiogenic therapy 
has been shown to cause an increase in lipid metabolism, leading to a rebound in 
tumour growth [127].
11.4.2 Autophagy
Tumours treated with anti-angiogenic agents may also adapt to survive by 
activation of autophagy. Autophagy can occur in response to treatment related 
stressors such as hypoxia and occurs when organelles and proteins in the cell are 
degraded and recycled by lysosomes [128]. Autophagy-mediating molecules such 
as BNIP3 have been identified in GBM tumour cells after exposure (a) to hypoxic 
conditions in vitro, (b) to bevacizumab therapy in vivo or (c) to bevacizumab 
therapy in human tumours [129]. Furthermore, a recent study has reported that 
when MDA-MB-231 breast cancer cells were treated with an agent that induced 
autophagy, they exhibited increased invasiveness [130].
11.4.3 Cancer stem cells (CSCs)
It is becoming clear that many solid tumours contain relatively rare subpopula-
tions of cancer stem cells. These are clones of tumour cells that are able to sustain 
self-renewal and can tolerate hostile environments [131]. Furthermore, it has been 
proposed that hypoxia induced by anti-angiogenic therapy can (a) select for CSCs, 
and (b) maintain the niche that supports the survival of CSCs [132]. Conceivably, 
these persistent clones of CSCs may render the tumour more invasive and meta-




Proposed mechanisms of resistance to anti-angiogenic therapy. (A–F) The potential mechanisms that tumours 
can utilise to evade anti-angiogenic therapy. (A) Vessel heterogeneity. Tumours can contain vessels that are at 
different stages of maturation making some more sensitive to therapy than others. For example, here the top 
vessel is immature and is abolished by therapy (grey), whilst the bottom one is mature and remains viable 
(red). (B) Alternative proangiogenic signalling pathway scan affect the susceptibility of vessels to therapy. 
Here, tumour cells (blue) have up-regulated an alternative pro-angiogenic growth factor to facilitate persistent 
blood vessel growth and survival despite VEGF blockade. (C) Stromal cells infiltrating into of the tumour, such 
as myeloid progenitors (black) or fibroblasts (green), can also mediate resistance by releasing pro-angiogenic 
growth factors or by physically incorporating into vessels. (D) Tumour cell adaptation to stress. Subpopulations 
of cancer cells in the tumour (blue) can survive the hypoxic conditions and nutrient shortage resulting from 
vascular destruction by employing different adaptation mechanisms. (E) Alternative tumour vascularisation 
mechanisms. Apart from sprouting angiogenesis, tumours may utilise alternative mechanisms to recruit a 
vascular supply. In intussusceptive microvascular growth, new vessels are generated by the fission of pre-
existing vessels. Glomeruloid angiogenesis is where tight nests of vessels, resembling the renal glomerulus, are 
formed. Vasculogenic mimicry is a process whereby tumour cells can create vascular-like structures themselves 
(blue) which are perfused as they become continuous with the host vasculature (red). In looping angiogenesis, 
contractile myofibroblasts (green) pull host vessels (red) out of the surrounding parenchymal tissue (pink 
region). Vessel co-option is a process whereby invading tumour cells engulf pre-existing vessels (red) in the 
normal parenchyma (pink region). (F) Selection of aggressive cells. Therapy alters the biology of the tumour 
cells in that they become more invasive and/or facilitate accelerated growth of metastases.
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11.4.4 Enhanced tumour aggressiveness
Anti-angiogenic therapy has been proposed to induce hypoxic tumour microen-
vironments, enhancing the aggressiveness of tumour cells (Figure 4F) [134]. This 
may help explain why the response to anti-angiogenic therapy is often transient 
as anti-angiogenic agents can cause initial reductions in tumour burden and a 
prolonged PFS, but with minimal or no improvement in OS [118]. Anti-angiogenic 
agents have demonstrated an ability to select for more aggressive cancer cells and 
enhance tumour cell invasion, growth and metastasis [135]. Moreover, it is now well 
accepted that some GBM patients with tumours treated with bevacizumab show an 
increase in tumour invasiveness [136].
11.5 Alternative vascularisation mechanisms
Despite the dogma that tumours primarily employ VEGF-dependent sprouting 
angiogenesis, emerging evidence now exists for alternative tumour vascularisation 
mechanisms, including: intussusceptive microvascular growth (IMG) (sometimes 
known merely as ‘intussusception’), glomeruloid angiogenesis, vascular mimicry 
(also sometimes called ‘vasculogenic mimicry’), looping angiogenesis, and vessel 
co-option (also sometimes called ‘vascular co-option’) (Figure 4E) [21]. These 
mechanisms may occur by alternative signalling pathways that may not be inhibited 
by VEGF-targeted therapies.
11.5.1 Intussusception
Intussusception is a mechanism whereby pre-existing vessels split into two 
daughter vessels without the need for endothelial cell proliferation and sprouting 
(Figure 4E). It has been observed in embryonic development and within experi-
mental tumours recovering from anti-angiogenic therapy and radiotherapy [137]. 
The molecular mechanisms that control this process are still not well understood.
11.5.2 Vascular mimicry
Vascular mimicry (VM) is a process observed in clinical and preclinical studies 
whereby tumour cells differentiate into vascular-like structures themselves [138] 
(Figure 4E). It has been shown that basic fibroblast growth factor (bFGF) and 
VEGF, are incapable of inducing VM channels and networks in poorly aggressive 
melanoma cell lines, suggesting that VM channel formation maybe be independent 
of these classical pro-angiogenic growth factors [139]. However, further mechanis-
tic detail is lacking.
11.5.3 Vessel co-option
Vessel co-option is the process whereby, when a tumour invades, exist-
ing local vessels become directly incorporated into the tumour (Figure 4E). 
Histopathological studies have indicated that colorectal and breast cancer liver 
metastases may utilise vessel co-option [140, 141].
Vessel co-option has been shown to mediate resistance to VEGF inhibitors in 
mouse models of melanoma metastasis to the brain and in mouse models of glio-
blastoma multiforme, and has been observed in glioblastoma patients who have 
progressed on anti-VEGF therapy [142–144]. Recently, it has been demonstrated 
that vessel co-option plays a role in mediating resistance to anti-angiogenic therapy 
in colorectal cancer liver metastases [145].
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In tumour samples obtained from primary lung cancer patients, gene expression 
arrays have been utilised to identify pathways differentially expressed between 
angiogenic tumours and vessel co-opting tumours [146]. Stromal expression of 
thrombospondin-1 appeared to be up regulated in angiogenic tumours, whilst in 
vessel co-option tumours, there was increased expression of genes involved in 
oxidative phosphorylation in primary [146]. Surprisingly, no differences in classic 
hypoxia or angiogenesis related genes were found between angiogenic and non-
angiogenic tumours.
In a glioma rat model of breast cancer brain and lung metastasis, co-opted blood 
vessels were seen in early-stage tumours and these vessels were found to overexpress 
angiopoietin-2, a natural antagonist of angiopoietin-1 [147]. As these tumours grew 
to become more hypoxic, VEGF was upregulated at the hypoxic tumour periphery 
and stimulated angiogenesis [147]. These observations suggest that a transition 
from vessel co-option to angiogenesis, or vice versa, may be dependent on the 
relative expression of pro-angiogenic growth factors (angiopoeitin-1, VEGF) and 
anti-angiogenic factors (angiopoeitin-2).
Cell adhesion molecules have been implicated in facilitating the process of vessel 
co-option. In a preclinical brain metastasis model, Carbonell et al. demonstrated 
that the β1 integrin subunit in breast cancer and lymphoma cells facilitates (a) 
tumour cell adhesion to the vascular basement membrane of existing brain vessels, 
(b) tumour cell invasion and (c) the process of vessel co-option [148]. When the 
function of the β1 integrin subunit was blocked, adhesion to vessels was attenuated 
and brain metastasis colonies failed to become established and grow [148].
Furthermore, the L1 cell adhesion molecule (L1CAM) has been shown to be 
involved in vessel co-option in the brain [149]. The ability of cancer cells to co-
opt blood vessels was suppressed when L1CAM expression was depleted using 
shRNA. Conversely, when L1CAM was overexpressed, tumour cells demonstrated 
enhanced adherence to the outer surface of vessels and tumour growth alongside 
them. Although such mechanisms are likely to be more specific for vessel co-option 
in the brain, similar mechanisms may be at work during vessel co-option at other 
anatomical sites.
12. Conclusion
Tumour vascularisation is modulated by the complex interplay of several 
endogenous factors and processes that can be up-regulated or downregulated, 
depending on the tumour microenvironment and the treatment pressures that are 
imposed on it. A multitude of studies have shown that the majority of solid tumours 
exhibit an overexpression of VEGF, one of the key drivers of sprouting angiogen-
esis. As a result, various anti-angiogenic therapies targeting VEGF or VEGFR have 
now been developed and are used conventionally in the clinic. Compellingly, recent 
pre-clinical and clinical studies using anti-angiogenic agents in combination with 
immunotherapies (e.g. ICI’s), have demonstrated a synergistic effect in reducing 
tumour growth. This highlights that there is promise, not only in incorporating 
anti-angiogenic therapy in the management of most cancers, but also in combining 
such agents with immunomodulatory agents.
However, as is the case with many cancer treatments, drug resistance can limit the 
efficacy of these agents. Trials of VEGF-targeted therapies in advanced malignancies 
have not consistently demonstrated beneficial outcomes in terms of tumour response 
and survival. Importantly, only a proportion of patients benefit from anti-angiogenic 
therapy, control of tumour growth is generally transient, there remains significant 
risk for therapeutic toxicity and we are still challenged by the burden of health costs.
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Limited clinical outcomes with anti-angiogenic therapies are felt to be driven by 
either intrinsic or acquired resistance mechanisms, and several of these have now 
been proposed. In this chapter, we have reviewed the most commonly used anti-
angiogenic agents in the clinic and have highlighted the spectrum of mechanisms 
that may be involved in therapeutic resistance. However, despite the plethora of 
pre-clinical and clinical studies that have been undertaken, these mechanisms are 
yet to be entirely elucidated. Importantly, the clinically relevant mechanisms that 
mediate such resistance to anti-angiogenic therapy are poorly understood and 
we still do not have means to select patients who will benefit from these agents. 
Furthermore, there has been a rapid expansion in the development of multiple next 
generation anti-vascular agents, but there is still little clarity regarding important 
biological pathways that may affect their efficacy.
The data supporting the role of candidate biomarkers for response and resis-
tance to anti-angiogenic therapies thus far have been generated from basic research, 
retrospective studies and limited prospective correlative studies. As such there 
remains a crucial need for substantial research of clinically relevant predictive 
biomarkers with the use of large, prospective randomised trials. This could also 
provide a platform for longitudinal and frequent biospecimen collection in order to 
further interrogate the mechanisms involved in tumour vascularisation and thera-
peutic resistance over time.
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